Gotham Asset Management LLC purchased a new stake in BioScrip Inc (NASDAQ:BIOS) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 39,028 shares of the company’s stock, valued at approximately $114,000.
A number of other large investors also recently made changes to their positions in the business. Gabelli Funds LLC grew its position in BioScrip by 2.0% in the fourth quarter. Gabelli Funds LLC now owns 10,357,832 shares of the company’s stock valued at $30,141,000 after acquiring an additional 205,379 shares during the period. BlackRock Inc. grew its position in BioScrip by 10.2% in the fourth quarter. BlackRock Inc. now owns 6,584,105 shares of the company’s stock valued at $19,161,000 after acquiring an additional 611,302 shares during the period. Royce & Associates LP grew its position in BioScrip by 942.6% in the fourth quarter. Royce & Associates LP now owns 1,824,500 shares of the company’s stock valued at $5,309,000 after acquiring an additional 1,649,500 shares during the period. Schwab Charles Investment Management Inc. grew its position in BioScrip by 4.9% in the third quarter. Schwab Charles Investment Management Inc. now owns 514,862 shares of the company’s stock valued at $1,416,000 after acquiring an additional 24,164 shares during the period. Finally, GSA Capital Partners LLP bought a new stake in BioScrip in the third quarter valued at $857,000. Hedge funds and other institutional investors own 84.33% of the company’s stock.
Shares of BIOS stock opened at $2.64 on Friday. The company has a current ratio of 1.79, a quick ratio of 1.42 and a debt-to-equity ratio of -5.65. The firm has a market cap of $301.37, a PE ratio of -6.00 and a beta of 0.11. BioScrip Inc has a 52 week low of $1.35 and a 52 week high of $3.39.
BIOS has been the topic of a number of analyst reports. SunTrust Banks set a $4.00 price target on BioScrip and gave the company a “buy” rating in a research report on Thursday, December 21st. BidaskClub upgraded BioScrip from a “hold” rating to a “buy” rating in a research report on Saturday, March 3rd. Craig Hallum reiterated a “buy” rating and issued a $3.50 price target on shares of BioScrip in a research report on Thursday, March 8th. Finally, Zacks Investment Research upgraded BioScrip from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $3.45.
ILLEGAL ACTIVITY WARNING: “Gotham Asset Management LLC Purchases Shares of 39,028 BioScrip Inc (BIOS)” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3337473/gotham-asset-management-llc-purchases-shares-of-39028-bioscrip-inc-bios.html.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.